Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 17/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118179 | 0.94 | GRM5 (0.45) | GRM5CYP3A4L3MBTL1 | |
| SCHEMBL5127834 | 0.92 | GRM5 (0.43) | GRM5CYP3A4L3MBTL1 | |
| SCHEMBL5117844 | 0.91 | GRM5 (0.44) | GRM5CYP3A4MEN1KMT2A | |
| SCHEMBL5130172 | 0.90 | GRM5 (0.41) | GRM5CYP3A4L3MBTL1 | |
| SCHEMBL5121804 | 0.86 | GRM5 (0.43) | GRM5CYP3A4L3MBTL1 | |
| SCHEMBL5123097 | 0.85 | GRM5 (0.43) | GRM5CYP3A4L3MBTL1MEN1KMT2A | |
| SCHEMBL5125423 | 0.80 | GRM5 (0.48) | GRM5CYP3A4L3MBTL1MEN1KMT2A | |
| SCHEMBL5114700 | 0.77 | GRM5 (0.46) | GRM5 | |
| SCHEMBL5128749 | 0.74 | NPC1 (0.48) | GRM5CYP3A4 | |
| SCHEMBL5129247 | 0.74 | GRM5 (0.48) | GRM5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| EP-1856107-A1 | PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS | Novartis AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006089700-A1 | PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS | NOVARTIS AG (CH) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | GRM5, GRIK5, GRM1 | GRM5 1/4885CYP3A4 2465/4885L3MBTL1 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.